UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of November 2024
Commission File Number: 001-39481
PainReform Ltd.
(Translation of registrant’s name into English)
65 Yigal Alon St., Tel Aviv 6744316
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No.
333-282264, 333-254982, 333-276485 and 333-277594).
PainReform Ltd. (the “Company”) is announcing that it will effect a reverse share split of the Company’s ordinary shares after market close on Wednesday, November 20, 2024, at
the ratio of 1-for-4, such that each four (4) ordinary shares, no par value, shall be consolidated into one (1) ordinary share, no par value. The first date when the Company’s ordinary shares will begin trading on the Nasdaq Capital Market after
implementation of the reverse split will be Thursday, November 21, 2024.
Following the implementation of the reverse split, the Company’s authorized share capital shall be comprised of 2,500,000 ordinary shares, no par value per share, and
approximately 590,616 ordinary shares shall be issued and outstanding.
No fractional ordinary shares will be issued as a result of the reverse split. All fractional ordinary shares will be rounded up to the nearest whole ordinary share. In addition,
a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase ordinary shares.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: November 18, 2024
|
PAINREFORM LTD.
|
|
|
|
|
|
By:
|
/s/ Ehud Geller
|
|
|
|
Ehud Geller
|
|
|
|
Interim Chief Executive Officer
|